CompanyPHATNasdaqFlorham Park, NJ

Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals commercializes vonoprazan, a potassium-competitive acid blocker for gastrointestinal diseases.

SEC EDGAR ClinicalTrials.gov phathompharma.com

8-KSep 29Latest SEC filing

Aug 26Latest story

August 2026

UNC registers Phase 4 trial testing Phathom's vonoprazan in Barrett's Esophagus

Aug 26Trial updatePhathom Pharmaceuticals, Inc.vonoprazan

Phathom registers Phase 3 trial testing vonoprazan for episodic heartburn relief in non-erosive GERD

Aug 7Trial updatePhathom Pharmaceuticals, Inc.vonoprazan

July 2026

Phathom to start Phase 3 as-needed VOQUEZNA trial in Q4 2026

Jul 30Quarterly updatePhathom Pharmaceuticals, Inc.vonoprazan